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The Role of the University in Promoting Human 
Embryonic Stem Cell Research and Stem Cell 
Therapies 
Dan S. Kaufman, MD, PhD, Associate Professor, Stem Cell 
Institute and Department of Medicine, Division of 
Hematology, Oncology, and Transplantation, Translational 
Research Facility, University of Minnesota 
When asked about what the University should do to 
support or promote stem cell research, my view as a physician-
scientist is that the University should allow and promote 
innovation. Specifically, innovation in a direction that will help 
us learn new knowledge about diseases and possible treatments 
to develop novel therapies that will push the envelope and help 
better treat and potentially cure those conditions that are 
currently incurable. As a faculty member in the Stem Cell 
Institute and the Department of Medicine at the University of 
Minnesota, my area of research interest is to use stem cells to 
understand blood cell development.  There are many different 
views on the question of how we push this field of stem cell 
research in general, and nuclear transfer in particular, toward 
novel clinical therapies. In my academic life, I routinely go back 
and forth between the clinic and the lab. This allows clear 
understanding of the needs and challenges in the areas of basic 
and clinical research, and how to potentially bring these areas 
together. 
As an example of the potential for successful stem cell 
therapies, it is informative to recall the scientific and 
technological innovation that developed in the field of 
hematology and bone marrow transplant (“BMT”).  The first 
successful BMT anywhere in the world was performed at the 
University of Minnesota in 1968.1  This was not the first BMT 
attempted, but was the first that succeeded. The patient was an 
 1. Richard A. Gatti et al., Immunological Reconstitution of Sex-Linked 
Lymphopenic Immunological Deficiency, 292 LANCET 1366, 1366–69 (1968). 
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infant with an immunodeficency that would typically be lethal 
because his body could not effectively fight common infections. 
He received bone marrow cells from his sister, and those cells 
engrafted his bone marrow and made all the blood cells he 
needs for an entire lifetime, including lymphocytes needed to 
fight infections.  It is important to recognize that bone marrow 
transplantation is stem cell therapy.  We can take bone marrow 
that contains blood stem cells from one person, typically a 
brother or sister, and transplant those to a patient with life 
threatening diseases, typically blood cell cancers or 
immunodeficiencies.2 Under the proper conditions those blood 
stem cells will live in the body of the recipient for the rest of 
his/her life. 
Thirty-eight years have passed since that first successful 
BMT, making that the longest period of time that we know a 
stem cell therapy will work.  However, even despite 
considerable progress over four decades, these transplants still 
have a high rate of problems that cause severe, potentially 
lethal side effects in the recipient.3  It still seems that the 
successful cases occur when the stars are aligned properly: you 
need the right donor and a recipient who is suffering from a 
life-threatening disease but not so sick that the treatment 
being done to save a life would unfortunately kill a patient 
instead.  We have learned about the types of cancers where 
stem cell therapy (in the form of BMT) is effective. However, 
20% or more of recipients of allogeneic transplants (from one 
person to another) will still die in the first year from the 
treatment alone.4 Therefore, because of the dangers involved in 
the procedures, we are still not going to do an allogeneic 
transplant in many cases. Despite thirty-eight years of 
research on this, this is how far we have advanced.  It is great 
for the patients when these transplants work—we can actually 
cure those diseases that would be otherwise be incurable. 
However, with the continued high rate of morbidity and 
mortality we are only going to do it on the most severe cases.  
For less severe diseases (i.e., autoimmune diseases), the benefit 
 2. Edward A. Copelan, Hematopoietic Stem-Cell Transplantation, 54 
NEW ENG. J. MED. 1813, 1813 (2006). 
 3. Id.; see also E. Donnall Thomas & Karl G. Blume, Historical Markers 
in the Development of Allogeneic Hematopoietic Cell Transplantation, 5 
BIOLOGY BLOOD & MARROW TRANSPLANTATION 341 (1999). 
 4. Copelan, supra note 2, at 1822. 
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may not be worth the risk. 
In my perspective, we now have an established experience 
and body of knowledge regarding stem cell-based treatments in 
the form of BMT.  We have room to make more real paradigm-
shifting treatment changes in the field of cancer therapy. 
Currently, if you have diseases such as lung cancer or multiple 
myeloma or kidney cancer, it is great for drug companies and 
those performing the clinical trials if the pharmaceutical 
companies develop a new drug that improves your life span by 
six months.  From my vantage point, however, this incremental 
advance is less then optimal.  We want treatments that will not 
just treat but cure the underlying diseases.  That is exactly 
what stem cell therapies have to offer.  There is considerable 
interest at the University of Minnesota to facilitate stem cell 
research using everything at our disposal to push this field 
forward in the most innovative and most productive way 
possible. These directions include adult stem cells, embryonic 
stem cells, and potentially nuclear transfer.  This is an 
important and rapidly developing area.  The Stem Cell 
Institute at the University of Minnesota (and at other 
institutions) helps promote advances to this field, but clearly 
we have a long way to go before we can successfully cure a wide 
range of devastating diseases.  The next ten years will be really 
exciting. New treatments and cures will come from these 
endeavors and support of stem cell research. However, it is also 
essential to communicate that many of these new treatments 
may not be directly cell-based therapies. Instead, these 
treatments will come about from these new cell-based assays 
and tools developed from the basic research.  In my view this is 
really where things are, and hopefully where the field is going. 
While I do not have formal training in bioethics, I certainly 
have a first hand perspective of the issues that are considered 
by patients, physicians, and researchers and have considered 
ethical and public policy issues related to human embryonic 
stem cell and nuclear transfer research. Clearly there are 
differences of opinion regarding ethical perspectives on this 
type of research. However, my view as a physician who cares 
for patients who die of cancer becomes quite clear, and I think 
typical for many working closely in this field, especially with 
patients who may one day benefit from advances in stem cell 
research.  I feel that it is actually morally imperative that stem 
cell research, that can and will impact so many diseases, be 
moved forward in as expeditious a manner as possible.  The list 
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of diseases that are often touted in terms of potential stem cell-
based therapies include spinal cord injury, diabetes, 
Parkinson’s disease, cancer, and others.  All of these diseases 
often have no good treatments and cause significant suffering 
and deaths of millions of patients every year.  Therefore, I 
think reinforcing what the role of the University in this process 
would be to facilitate working with policy makers, as well as 
have appropriate oversight by ethical and clinical trial review 
committees, so that these basic research studies and eventual 
clinical trials can be done in as open and productive a manner 
as possible. This is an exciting area of research that implicates 
science, ethics, and public policy in a field that truly represents 
twenty-first century medicine. 
